Accordingly, we hypothesized that AC/CC genotypes of the AQP5 -1364A/C promoter polymorphism are associated with a lower risk for MAKE30 (i.e., incidence for AKI, death, new RRT, and persistent renal dysfunction within the first 30 days) and also demonstrate higher 90-day survival. This evidence concerns the gene AQP5 and acute kidney injury.